Striving for a better future, Silenseed is dedicated towards developing drugs and drug delivery platforms that create a novel treatment for solid tumors. Harnessing new scientific horizons, we are developing solutions for untreated cancers and innovative ways for RNAi drug delivery.
Motivated by the challenges facing RNAi delivery, Silenseed is developing a novel drug delivery platform in collaboration with EVONIK Corporation. Our Microparticle siRNA enables the insertion of RNAi therapeutic pharmaceuticals directly into the core of solid tumor.
With patients in mind – Silenseed is dedicated towards developing novel drugs that harness new scientific horizons developing solutions for untreated cancers
March 23rd 2023 Modiin Israel. Silenseed announced today the filing of a new provisional patent application named: Immunogenic KRAS...
December 15th 2022 Modiin Israel. Silenseed announced today the filing of a new provisional patent application named: COMPOSITION FOR...
Israel-based Silenseed, a clinical-stage biopharmaceutical company, has announced that it has signed a Joint Venture Agreement with Guangzhou Sino-Israel...
